Cross-border fintech Airwallex raises $100M Series D extension at new valuation of $2.6B

Catherine Shu
·1 min read

Airwallex, the fintech company for cross-border businesses, announced today it has added $100 million more to its Series D round, bumping its valuation up to $2.6 billion. The extension was led by Greenoaks, with participation from Grok Ventures and returning investors Skip Capital and ANZi Ventures.

Co-founder and chief executive officer Jack Zhang told TechCrunch that the new funding will be used for Airwallex's United States launch in the second quarter of this year, to expand its payment coverage to new regions like the Middle East, Africa, Eastern Europe and Latin America, and to add more products, including physical cards.

This latest extension brings Airwallex’s Series D round to $300 million, and total equity raised so far to $500 million. Airwallex first announced its Series D in April 2020 after raising $160 million, then another tranche that added $40 million in September 2020.

Airwallex gets $160 million Series D to launch more cross-border financial products

Airwallex reached unicorn valuation after its Series C in March 2019. The company was founded in Melbourne in 2015, and now has more than 600 employees across 12 offices in Australia, China, Hong Kong, the United Kingdom, Japan and the United States. In its announcement today, Airwallex said it is also hiring for more than 500 positions.

Airwallex’s products for cross-border businesses include foreign currency accounts and multi-currency debit cards with Visa, international money transfers and a suite of APIs that allow companies to do things like accept and manage international payments, and manage their foreign exchange risk.

All B2B startups are in the payments business

Remessa Online raises $20 million to become the TransferWise of Latin America

On the heels of its next fundraise, cross-border payments upstart Payoneer acquires optile

 

Latest Stories

  • France advises citizens to leave Pakistan after serious threats: sources

    France has advised French citizens to temporarily leave Pakistan and warned of serious threats to French interests in the country, two diplomatic sources said on Thursday, after violent clashes there this week. The diplomatic sources said that a message had been sent overnight to French citizens and companies following threats by hardline Islamist group Tehrik-i-Labaik Pakistan (TLP) to target French interests.

  • Global Railway Signalling System Market Report 2021-2025 - Rising Investment in Urban Transportation Particularly in Railway Networks is Increasing the Demand for CBTC Systems - ResearchAndMarkets.com

    The "Railway Signalling System Market Research Report by Technology - Global Forecast to 2025 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

  • ‘Das Boot’ Producer Moritz Polter to Join ITV Studios, Create High-End Scripted Label

    Moritz Polter, executive producer of Sky series “Das Boot” and “Freud” for Netflix/ORF, is joining ITV Studios and establishing a high-end German scripted label. The label will be launched later in 2021. Moritz will be based in Germany with an international scope and will report into Lisa Perrin, managing director of international production at ITV […]

  • Global Ambulance Services Market 2021-2028 - Rising Medical Tourism and an Increasing Number of Road Accidents and CVD Cases to Drive Demand

    Dublin, April 15, 2021 (GLOBE NEWSWIRE) -- The "Ambulance Services Market Size, Share & Trends Analysis Report by Transport Vehicle (Ground, Water, Air), by Emergency Services (Emergency, Non-emergency), by Equipment, by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering. The global ambulance services market size is expected to reach USD 67.7 billion by 2028 and expected to expand at a CAGR of 9.6% from 2021 to 2028. Rising medical tourism and an increasing number of road accidents and CVD cases are the key driving factors for the market.The growth of the market is due to favorable reimbursement policies in developed nations. In the U.S., Medicare covers both non-emergency and emergency ambulance services for medically necessary cases, if the supplier fulfills stipulated requirements. In some circumstances, Medicare also covers unscheduled and irregular non-emergency trips. Medicare covers 80.0% of the approved amount for emergency medical services and the remaining 20.0% is covered by the supplemental insurance policy of the patient. In New Jersey, Pennsylvania, and South Carolina, for repetitive, non-emergency trips, patients need prior authorization from Medicare Administrative Contractor (MAC). However, Medicare does not pay for ambulates (wheelchair-accessible vans that provide non-emergency transportation services).In Victoria, Australia, patients can avail of emergency medical services by securing membership with Ambulance Victoria, which offers emergency medical services at subsidized prices. Ambulance Tasmania provides free emergency medical services to residents of Tasmania. Residents of Queensland (Australia) are covered with the cost of emergency services across Australia, by the QLD state government. Similarly, in the U.K., the public healthcare system provides free emergency and non-emergency medical services. In addition, patients receive NHS funding for their treatment. In Germany, public health insurance (Gesetzliche Krankenversicherung) is compulsory for every citizen and this insurance also covers non-emergency and emergency medical services. Private health insurance (Private Krankenversicherung) is usually opted by those who have high yearly income. Ease of payment through reimbursement policies encourages patients to opt for emergency medical services more frequently, which is likely to bolster the growth of the market.Ambulance Services Market Report Highlights In terms of revenue, the ground ambulance segment held the largest share in 2020. The rising number of road accidents and increasing COVID-19 cases across the globe are major factors propelling segment growth.The emergency services segment held the largest market share in 2020 and is expected to grow fast over the forecast period due to the increasing number of CVDs.The Advanced Life Support (ALS) ambulance services segment held the largest market share in 2020. The growth of the segment is majorly driven by the increasing medical tourism across the globe.In Asia Pacific, the market is expected to witness the fastest growth rate over the forecast period owing to the rising number of COVID-19 cases in the region. Key Topics Covered: Chapter 1 Research MethodologyChapter 2 Executive SummaryChapter 3 Industry Outlook3.1 Market Segmentation3.2 Market Variable Analysis3.2.1 Market driver analysis3.2.1.1 Favorable reimbursement policies3.2.1.2 Entrance of new ambulance service providers globally3.2.1.3 Rising medical tourism3.2.1.4 Increasing number of road accidents3.2.1.5 Rising CVD3.2.1.6 Increasing geratric population3.2.2 Market restraint analysis3.2.2.1 High cost of air ambulances3.2.2.2 Stringent regulations by the Federal Aviation Administration (FAA)3.3 Penetration & Growth Prospect Mapping3.4 Business Environment Analysis tools3.4.1 SWOT Analysis, by PEST3.4.2 Porter's five forces analysisChapter 4 Transport Vehicle Segment Analysis4.1 Ambulance Services Market: Transport Vehicle Movement Analysis4.2 Ground Ambulance4.3 Air Ambulance4.4 Water AmbulanceChapter 5 Emergency Services Segment Analysis5.1 Ambulance Services Market: Emergency Services Movement Analysis5.2 Emergency Services5.3 Non-emergency ServicesChapter 6 Equipment Segment Analysis6.1 Ambulance Services Market: Equipment Movement Analysis6.2 Advanced Life Support (ALS) Ambulance Services6.3 Basic Life Support (BLS) Ambulance ServicesChapter 7 Regional Outlook7.1 Ambulance Services Market Share by Region, 2020 & 2028Chapter 8 Company Profiles8.1 Company overview8.2 Financial performance8.3 Product benchmarking8.4 Strategic initiatives8.5 SWOT analysis Envision HealthcareLondon Ambulance Service Nhs TrustAcadian Ambulance ServiceBvg India LimitedAmerica Ambulance Services, Inc.Falck Denmark A/SAir Medical Group Holdings, Inc. (Amgh)Air Methods CorporationZiqitza Healthcare LimitedMedivic Aviation For more information about this report visit https://www.researchandmarkets.com/r/62x6ma CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

  • Billionaire MyProtein boss donates £100m to charity as sales surge 40% to £1.6bn

    Matthew Moulding and his family established The Moulding Foundation in 2020.

  • U.S. Sanctions Sink Russian Ruble, Bonds as New Sanctions Planned

    (Bloomberg) -- Russian bonds sank the most since March last year and the ruble tumbled as the U.S. prepared to unveil sanctions on the nation’s local debt, a threat that has dimmed investor appetite for the market for years.The yield on ruble debt due in 10 years jumped the most since the peak of the pandemic-driven market turmoil. Stocks snapped three days of gains and the Russian currency dropped the most since December, erasing a rally spurred earlier in the week by U.S. President Joe Biden’s proposal for a summit with Vladimir Putin.The planned measures include barring U.S. financial institutions from participating in the primary market for new debt issued by the Russian central bank, Finance Ministry and sovereign wealth fund, according to a person familiar with the package of sanctions expected to be announced this week. The precise timing of the bond measures wasn’t clear, they said.READ MORE: U.S. to Impose Russia Sanctions Over Election, SolarWindsPenalties on government OFZ bonds would be “something new for the market,” said Iskander Lutsko, a strategist at ITI Capital in Moscow. “A recovery will depend on how the Russian authorities react -- if it’s muted, then markets will claw back ground, but if the planned meeting with Biden is canceled and there’s tough rhetoric, then the pressure will only increase.”Once seen as too big a risk for markets, the bond sanctions are becoming a reality after Russia’s troop buildup on the border with Ukraine sent tensions with the West spiraling. Penalties focusing on Russian individuals and entities could be announced as early as Thursday and come in retaliation for alleged Kremlin misconduct including the SolarWinds hack and efforts to disrupt the U.S. election.READ MORE: Putin’s Ukraine Gambit Turns Debt Sanctions Into a Real ThreatAnalysts at JP Morgan Chase & Co. downgraded the ruble and Russian bonds last week, citing the escalating tensions and the risk that U.S. investors might close long positions on OFZs.Russian officials say bond sanctions wouldn’t cause much damage to Russia’s financial markets because local banks and non-U.S. investors would step in to replace those forced to sell. A move to ban U.S. banks from buying new issues of Russian Eurobonds in 2019 did little to dent the Kremlin’s access to foreign funding.VTB Bank PJSC bought more than 70% of the local notes on offer in debt sales on Wednesday, which saw a record placement equivalent to almost $3 billion.State Backup“It is OFZ- and ruble-negative in the near-term,” ING Groep NV economist Dmitry Dolgin said from Moscow. “The market has been speculating on the likelihood of that for a couple of years, and since mid-2020 the perceived risk of sanctions went up, and the ruble’s discount to its emerging-market and commodity-producing peers doubled.”After climbing 27 basis points at the start of trading, yields on Russia’s 10-year ruble bonds were up 19 basis points at 7.23% as of 11:21 a.m. in Moscow, set for the biggest increase since August. The ruble traded 1.3% weaker at 76.85 per dollar, after a drop of as much as 2.1%. Russia’s benchmark MOEX stock index snapped three days of gains with a 0.8% retreat.On Thursday, investors were waiting for further details of the planned restrictions.Which institutions are covered by the sanctions may be key, especially if it affects the world’s biggest bond clearing systems, according to Paul McNamara, an emerging-markets investor at GAM Investments in London.“Does that include any financial institution with a U.S. operation? Or, conceivably, U.S. clients,” he said. “If it affects Euroclear and Clearstream that’s a bigger deal, but most OFZs don’t go via those systems, even held by foreigner.”For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Pay package looms large as Orcel takes helm at UniCredit

    Andrea Orcel will fulfil his dream of becoming a bank boss on Thursday when UniCredit investors back the veteran dealmaker as chief executive, but disquiet over his pay, among the highest for a banker in Europe, means his tenure begins on the defensive. Orcel only narrowly defeated a shareholder revolt over the terms and size of his up to 7.5 million euro ($9 million)remuneration package, Italian daily la Repubblica reported on its website late on Wednesday. UniCredit declined to comment.

  • After late call, Jacob Bernard-Docker makes NHL debut with the Ottawa Senators

    Apr. 15—The Ottawa Senators did not originally intend on having Jacob Bernard-Docker make his NHL debut Wednesday night. The defenseman, just two weeks from being a college student at UND, only had practiced one time with the Senators after serving his mandatory seven-day quarantine. But at morning skate, the coaching staff gave Bernard-Docker a heads up that defenseman Nikita Zaitsev wasn't ...

  • Gyms seeing return of people to exercise

    Apr. 15—Different fitness and exercise facilities in Owensboro-Daviess County have worked their way through a year of COVID-19 regulations and protocols. Capacity levels have been settled in at 50-60%, with active social distancing, cleaning, and mask wearing protocols still in place. Exercise and gym facilities contacted were all saying masks were required to come in and workout. "Masking is ...

  • Valley to Summit: Former UND linebacker could be drafted in Thursday's CFL Global Draft

    Apr. 15—Note: The Valley to Summit series is a daily roundup of items from the Missouri Valley Football Conference and the Summit League as it relates to UND sports. Former UND linebacker Tyron Vrede's long, interesting path in football could reach new heights Thursday afternoon. The Canadian Football League will hold its Global Draft on Thursday, beginning at noon. A popular CFL web site, 3 ...

  • UK politics news - live: Third inquiry into Greensill lobbying announced, as Cameron will give evidence to MPs

    Live updates on UK politics

  • Frost & Sullivan Examines Global Opportunities for Fuel Cell Trucks in Hydrogen Economies

    The global automotive industry is rapidly evolving in terms of technology and tackling environmental issues. The development of hydrogen fuel cells for mobility applications is gaining traction as global economies strive to achieve zero-emission targets. In line with this clean energy goal, governments and original equipment manufacturers (OEMs) are expediting progress to achieve commercial-scale deployment of fuel cell electric vehicles (FCEVs), identifying potential opportunity areas in trucking applications and related ecosystems.

  • Accused road rage killer due in court

    The man accused of murdering a mother of six in a road rage shooting is scheduled to be in court Thursday.

  • Police smash door and arrest man who failed to hotel quarantine after travel from red list country

    Man from Liverpool told he must isolate in government-approved accomodation for 10 days but returns home

  • Turkey to send delegation to Egypt in May, foreign ministers to meet later

    Turkey will send a delegation led by its deputy foreign minister to Egypt in early May, Foreign Minister Mevlut Cavusoglu said on Thursday, as Ankara ramps up a push to repair strained ties with Cairo after years of animosity. Last month, Turkey said it had resumed diplomatic contacts with Egypt and wanted to further cooperation, eight years after ties crumbled over the Egyptian army toppling a Muslim Brotherhood president close to Ankara in 2013.

  • Global Hepatocellular Carcinoma Market Analysis 2019-2020 & 2029 - High Level of Unmet Needs Leaves Room for Further Research & Opportunity for Pipeline Agents with First-in-Class Approvals

    Dublin, April 15, 2021 (GLOBE NEWSWIRE) -- The "Hepatocellular Carcinoma - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering. The pipeline drugs in development for HCC are mostly already approved for other indications and HCC represents a growth strategy for the brands. There are currently nine pipeline products in Phase III clinical trial; additionally, seven marketed agents are in clinical trials to expand their labels in new lines of therapy and new combinations within HCC. The most common MOAs under investigation for HCC include tyrosine kinase inhibitors (TKI) and immuno-oncology (IO) agents (programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitors). In addition to the active late-stage pipeline, there are a large number of ongoing Phase I and II trials. Hepatocellular carcinoma (HCC) is the most frequent type of primary malignancy of the liver. The prognosis of HCC is dependent on the stage of the disease at diagnosis. However, even with treatments such as surgical resection, liver transplantation, and ablative therapies, which are only suitable for early-stage HCC patients, the majority of patients are likely to progress onto the advanced stages of the disease. Until the entry of Roche's combination therapy of Avastin + Tecentriq in May 2020, Bayer's multikinase inhibitor commanded the largest first-line and second-line patient share in the HCC market. This led to a shift in multikinase inhibitor monotherapy as standard of care (SOC) and initiated a new strategy in the HCC market whereby combinations are now the predominant therapeutic option under development.Key Highlights Upon approval of Avastin + Tecentriq by the FDA, in May 2020, the combination replaced the SoC in first-line advanced HCC, shifting Nexavar and Lenvima to second-line treatment options.The greatest drivers of growth in the global HCC market include the launch of new pipeline therapies, combinations of therapies with different MOAs, label expansion from other oncology indications to HCC, and label expansion into earlier lines of therapy, in addition to an increase in diagnosed incident cases in many 8MM countries.The main barrier to growth in the HCC market is patent expiration of key biologic brands with subsequent biosimilar launch.The most important unmet needs in the HCC market are better HCC surveillance and prophylactic treatments, curative therapies in early-stage HCC, improved survival for intermediate-stage HCC, data on sequencing of treatments, prognostic biomarkers, treatments for patients with impaired liver function. Key Topics Covered: 1 Tables & Figures2 Hepatocellular Carcinoma: Executive Summary2.1 Global HCC Market Expected to Grow at 17.7% CAGR to $5.3B During 2019-20292.2 Competitive Market with New Strategies to Gain Patient Share in the HCC Market2.3 High Level of Unmet Needs Leaves Room for Further Research2.4 Opportunity for Pipeline Agents with First-in-Class Approvals2.5 What Do Physicians Think?3 Introduction3.1 Catalyst3.2 Related Reports3.3 Upcoming Related Reports4 Disease Overview4.1 Etiology4.1.1 HBV and HCV Infection4.1.2 Alcohol4.1.3 NAFLD4.2 Pathophysiology4.2.1 MAPK Pathway4.2.2 PI3K/Akt Pathway4.2.3 Wnt/catenin Pathway4.2.4 JAK/STAT Pathway4.3 Surveillance of HCC4.4 Biomarkers4.5 Clinical Staging and Treatment Guidelines4.6 Prognosis and Progression5 Epidemiology5.1 Disease Background5.2 Risk Factors and Comorbidities5.3 Global and Historical Trends5.4 Forecast Methodology5.5 Epidemiological Forecast for HCC5.6 Discussion5.6.1 Epidemiological Forecast Insight5.6.2 COVID-19 Impact5.6.3 Limitations of Analysis5.6.4 Strengths of Analysis6 Current Treatment Options6.1 Overview6.2 Curative Therapy6.2.1 Surgical Approaches: Transplant and Resection6.2.2 Local Ablative Therapies6.3 Non-curative/Palliative Therapy6.3.1 Transarterial Regional Therapies6.3.2 Systemic Therapy7 Unmet Needs and Opportunity Assessment7.1 Overview7.2 Better HCC Surveillance and Prophylactic Treatments7.3 More Effective Treatments7.3.1 Curative Therapies in Early-Stage HCC7.3.2 Improved Survival for Intermediate-Stage HCC7.4 Data on Sequencing of Treatments7.5 Prognostic Biomarkers7.6 Treatments for Patients with Impaired Liver Function8 R&D Strategies8.1 Overview8.1.1 Combination Therapies with Different MOAs8.1.2 Label Expansion from Other Oncology Indications to HCC as Part of Lifecycle Management8.1.3 Label Expansion into Earlier Lines of Therapy8.2 Clinical Trials Design8.2.1 Clinical Trial Design Flaws8.2.2 Appropriate Active Comparator in HCC Clinical Trials9 Pipeline Assessment9.1 Overview9.1.1 Adjuvant Treatment9.1.2 Intermediate HCC9.1.3 Advanced HCC9.2 Innovative Early-Stage Approaches9.3 Other Drugs in Development10 Pipeline Valuation Analysis10.1 Clinical Benchmark of Key Pipeline Drugs10.1.1 Adjuvant Treatment10.1.2 Intermediate HCC10.1.3 Advanced HCC10.2 Commercial Benchmark of Key Pipeline Drugs10.2.1 Adjuvant Treatment10.2.2 Intermediate HCC10.2.3 Advanced HCC10.3 Competitive Assessment10.3.1 Adjuvant Treatment10.3.2 Intermediate HCC10.3.3 Advanced HCC10.4 Top-Line 10-Year Forecast10.4.1 US10.4.2 5EU10.4.3 Japan10.4.4 China11 Appendix Companies Mentioned AstraZenecaBayerBMSOnyx PharmaceuticalsEisaiExelixisRoche/GenentechMerck & Co.NovartisOnoImClone SystemsSuzhou Zelgen BiopharmaceuticalJiangsu Hengrui MedicineBeiGene LtdCStone Pharmaceuticals CoInnovent BiologicsShanghai Junshi Bioscience For more information about this report visit https://www.researchandmarkets.com/r/33na7h CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

  • Nearly 400,000 NHS patients in England waiting more than a year for treatment

    Nearly 400,000 NHSpatients in England have now been waiting more than a year for routine treatment, according to the latest NHS performance data. According to NHS England a total of 387,885 patients had been waiting over a year for planned surgery and other routine treatments – this has increased from just 1,613 a year ago and is the highest number for any month since December 2007. Hospitals across England treated almost 140,000 Covid patients in February, with NHS England saying more than 400,000 patients with the virus have been treated in hospital during the pandemic.

  • German economy probably shrank 1.8% last quarter due to COVID lockdown, institutes say

    The German economy probably shrank by 1.8% in the first quarter because of COVID-19 restrictions, leading economic institutes said on Thursday as they revised their joint growth forecast for Europe's largest economy. The institutes now expect gross domestic product to grow by 3.7% this year, down from their previous forecast of 4.7%. The institutes estimate that COVID-19 restrictions have led households to save some 200 billion euros ($239.54 billion), Torsten Schmidt from the RWI institute said.

  • Soaking rain: Updated 7-day forecast

    Soaking rain moves in to the Tri-State area Thursday, with the heaviest showers hitting the city to the north and east.

  • UPDATE 1-German economy probably shrank 1.8% last quarter due to COVID lockdown, institutes say

    The German economy probably shrank by 1.8% in the first quarter because of COVID-19 restrictions, leading economic institutes said on Thursday as they revised their joint growth forecast for Europe's largest economy. The institutes now expect gross domestic product to grow by 3.7% this year, down from their previous forecast of 4.7%. The institutes estimate that COVID-19 restrictions have led households to save some 200 billion euros ($239.54 billion), Torsten Schmidt from the RWI institute said.